Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at SMR 2016 Congress
- IMCgp100 demonstrates clear early evidence of monotherapy activity in patients with uveal melanoma
- Pivotal Phase II clinical study on track to be initiated in first quarter 2017
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, will present positive data from its Phase I clinical monotherapy trial in uveal melanoma (UM) of its lead product, IMCgp100, an ImmTAC (Immune mobilising monoclonal TCRs Against Cancer). These data demonstrate clear early evidence of monotherapy activity of IMCgp100 in patients with uveal melanoma and strengthens the data announced at ASCO 2016.